Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial
Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators
Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung
263Zitate
(Scopus)
Fingerprint
Untersuchen Sie die Forschungsthemen von „Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial“. Zusammen bilden sie einen einzigartigen Fingerprint.